|
Gemtuzumab Ozogamicin Clinical Trials
10 actively recruiting trials across 5 locations
Also known as: CDP-771, CMA-676, Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody, Mylotarg, WAY-CMA-676 +2 more
Pipeline
Phase 1: 1Phase 2: 5Phase 3: 4
Top Sponsors
- M.D. Anderson Cancer Center3
- University of Washington1
- University of Birmingham1
- PedAL BCU, LLC1
- National Cancer Institute (NCI)1
Indications
- Cancer10
- Acute Myeloid Leukemia7
- High-risk Myelodysplastic Syndrome2
- Acute Promyelocytic Leukemia With PML-RARA1
- Heart Disease1
Houston, Texas3 trials
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
M D Anderson Cancer Center
Phase 2
Other2 trials
Birmingham, Alabama2 trials
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Children's Hospital of Alabama
Phase 3
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
University of Alabama at Birmingham Cancer Center
Phase 2
Phoenix, Arizona1 trial
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Phoenix Children's Hospital
Phase 3
Tampa, Florida1 trial
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
Moffitt Cancer Center
Phase 1
Seattle, Washington1 trial
Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia
Fred Hutchinson Cancer Center/University of Washington Cancer Consortium
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.